Therapeutic drug monitoring: A pharmacotherapeutic tool in psychiatry;Arzneimittelspiegel als pharmakotherapeutisches werkzeug bei der behandlung mit psychopharmaka

Praxis

Volumn 95, Issue 17, 2006, Pages 671-678

  Stephan, P L ^a   Etzensberger, M ^a   Jaquenoud Sirot, Eveline ^a  

^a Psychiatrische Dienste Aargau AG   (Switzerland)

Author keywords

Outpatients; Pharmacogenetics; Psychiatry; Psychotropic drugs; Recommendations; Therapeutic drug monitoring

Indexed keywords

EID: 80051680684     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/0369-8394.95.17.671     Document Type: Review

References (18)

1. Jaquenoud Sirot E, Eap CB, Baumann P: Bedeutung von TDM und Pharmakogenetik bei Untersuchungen über Arzneimittelsicherheit in der Psychiatrie. Psychopharmakotherapie 2003;10:5-10 (Pubitemid 36249493)
2. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M et al. The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004;37:243-265 (Pubitemid 39587052)
3. Lin JH, Yamazaki M: Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003;42:59-98 (Pubitemid 36092258)
4. Grohmann R, Engel RR, Ruether E, Hippius H: The AMSP drug safety program: methods and global results. Pharmacopsychiatry 2004;37:S4-11
5. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD: The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001;70:317-26 (Pubitemid 33022472)
6. Wang LS, Zhu B, El-Aty AM et al.: The influence of St John's Wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol 2004;44:577-81. (Pubitemid 38668019)
7. Hennessy M, Kelleher D, Spiers JP et al.: St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002;53:75-82 (Pubitemid 34117742)
8. Yin OQ, Tomlinson B, Waye MM, Chow AH, Chow MS: Pharmcogenetics and herb-drug interactions: experience with ginkgo biloba and omeprazole. Pharmacogenetics 2004;14:841-50 (Pubitemid 40054339)
9. Fattinger K, Meier-Abt A: Interaktionen zwischen Phytopharmaka und Arzneimitteln. Schweiz Med Forum 2003;29/30:693-700
10. Schein JR: Cigarette smoking and clinically significant drug interactions. Ann Pharmacother 1995;29:1139-48
11. Sachse C, Brockmöller J, Bauer S, Roots I: Functional significance of a C?A polymorphism in Intron I of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47:445-9 (Pubitemid 29161279)
12. Haag S, Spigset O, Mjornadal T, Dahlqvist R: Effects of caffeine on clozapine pharmacokoinetics in healthy volunteers. Br J Clin Pharmacol 2000;49:59-63 (Pubitemid 30050487)
13. Raaska K, Raitasuo V, Laitila J, Neuvonem PJ: Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalised patients. Basic Clin Pharmacol Toxicol 2004;94:13-8 (Pubitemid 38428815)
14. Sinclair J, Jeffery E, Wrighton S et al.: Alcohol-mediated increases in acetaminophen hepatotoxicity: role of CYP2E and CYP3A. Biochem Pharmacol 1998;55:1557-65 (Pubitemid 28223447)
15. FDA announces new alcohol warnings for pain relievers and fever reducers (1998). U.S. Food and Drug Administration Web site: http://www.fda.gov/bbs/ topics/NEWS/NEW00659.html (Stand 21.03.06)
16. .Takanaga H, Ohnishi A, Murakami H et al: Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Clin Pharmacol Ther 2000;67:201-14 (Pubitemid 30176377)
17. Lampe JW, King IB, Li S et al.: Brassica vegetables increase and apiceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolites ratios in response to controlled vegetables diets: Carcinogenesis 2000;21:1157-62 (Pubitemid 30389341)
18. .AGNP Web site: http://www.agnp.de/AGNP-Homepage-Dateien/Downloads/ Consensus.pdf (Stand 21.03.06)